0.425
-0.05 (-10.95%)
| Penutupan Terdahulu | 0.478 |
| Buka | 0.493 |
| Jumlah Dagangan | 258,323 |
| Purata Dagangan (3B) | 802,124 |
| Modal Pasaran | 14,628,883 |
| Harga / Jualan (P/S) | 0.030 |
| Harga / Buku (P/B) | 0.120 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Feb 2026 |
| Margin Keuntungan | -18.21% |
| Margin Operasi (TTM) | -7.62% |
| EPS Cair (TTM) | -3.12 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 4.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 286.38% |
| Nisbah Semasa (MRQ) | 1.50 |
| Aliran Tunai Operasi (OCF TTM) | -34.49 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -11.40 M |
| Pulangan Atas Aset (ROA TTM) | -2.31% |
| Pulangan Atas Ekuiti (ROE TTM) | -47.95% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Menaik |
| Diagnostics & Research (Global) | Menaik | Menaik | |
| Stok | Inotiv, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.31% |
| % Dimiliki oleh Institusi | 23.66% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Massar Capital Management, Lp | 30 Sep 2025 | 350,000 |
| Vantage Point Financial Llc | 31 Dec 2025 | 336,546 |
| Acorn Creek Capital Llc | 31 Dec 2025 | 158,750 |
| Mount Lucas Management Lp | 30 Sep 2025 | 143,500 |
| Julat 52 Minggu | ||
| Median | 3.00 (605.38%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Lake Street | 04 Dec 2025 | 3.00 (605.38%) | Beli | 0.880 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jan 2026 | Pengumuman | Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery |
| 11 Dec 2025 | Pengumuman | Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities |
| 03 Dec 2025 | Pengumuman | Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update |
| 25 Nov 2025 | Pengumuman | Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™ |
| 21 Nov 2025 | Pengumuman | Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025 |
| 17 Nov 2025 | Pengumuman | Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |